Neoptolemos was born in Pano Zodhia, Cyprus and raised in London. He graduated from the University of Cambridge (Churchill College) (1970-1973), and at Guy's Hospital, London (1973-1976). Neoptolemos completed his academic and clinical training in Leicester under the tutelage of Professor Sir Peter Bell,[11][12] being awarded a Doctorate in Medicine in 1986 for his thesis "Effect of surgery on monocyte function in patients with colorectal cancer".[13] During surgical training in Ulm he met Markus Büchler, together setting up the European Study for Pancreas Cancer Research (ESPAC)[14] later.
After appointments at the University of Birmingham, Neoptolemos was elected Chair of Surgery of Liverpool University and Head of Department of Surgery in 1996[15][16] to focus on pancreas disease research together with Professor Ole Petersen for the University,[17][18] and to develop the surgical services of the Royal Liverpool University Hospital.[19] Neoptolemos became the director of the newly established Liverpool Clinical Trial Unit (LCTU)[20] from 1996 and the chairman of the Pancreas Tumour Multi-Disciplinary Team at the Royal Liverpool University Hospital from 2001.[21] Neoptolemos and Petersen established the National Institutes of Health Research (NIHR) Pancreas Biomedical Research Unit from 2007, renewed again in 2012.[19]
In 2005 he became head of the new School of Cancer Studies.[22]
From 2007 he became the director of the Cancer Research UK Liverpool Cancer Trials Unit.[23]
Neoptolemos was co-director of the CRUK and NIHR Liverpool Experimental Cancer Centre from 2007 until 2012 and from then the director of the LCTU GCP Labs as well as the director the CRUK from 2011 until 2013.[24] The Cancer Research UK Liverpool Centre received the Freedom of the City of Liverpool[25][26] on 8 February 2012.
In 2014 the LCTU Cancer Research UK Liverpool Cancer Trials Unit received accreditation as National Cancer Research Institute (NCRI) Cancer Trials Unit.[20] The associated Pancreas Unit became the Health Services Journal National Award Winner in 2013.[27]
National and international scientific role
Neoptolemos was the Clinical Chair for the NICE Guidelines on Pancreatic Cancer (2015-2017).[28] John Neoptolemos has been Secretary and President of the European Pancreas Club (EPC),[29] as well as President of the Pancreatic Society of Great Britain and Ireland[30] and the International Association of Pancreatology[31] (IAP).[32] As IAP President he developed the first IAP Guidelines in 2003 – on acute pancreatitis.[33]
Neoptolemos received international recognition including the Lifetime Achievement Award of the EPC[34] (2013); the Ruth Brufsky Award for Pancreas Cancer Research[35] (2017); and the Henry Lynch Award for Inherited Pancreas Diseases[36] (2018).
Scientific merits
In 1989 Neoptolemos was the founder of the European Study for Pancreas Cancer Research (ESPAC)[37][38] that has led the way for internationally collaborative pancreas cancer trials (ESPAC 1-4 trials[39][40][41]). The ESPAC-1 trial was the first trial to establish the benefit of adjuvant treatment in pancreatic cancer favoring chemotherapy[42] rather than chemoradiotherapy.[43][44] In 1997 he established the European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC)[45][46] for the study of genetic pancreatic diseases. In 2005 Neoptolemos co-founded the International Study Group for Pancreas Surgery (ISGPS) with Markus Büchler (Ulm) and others.[47]
Awards and honors (selection)
The Lord Smith Medal, Pancreatic Society of Great Britain and Ireland 1987[48]
Beger HG, Warshaw A, Carr-Locke DL, Russell RCG, Buchler M, Neoptolemos JP, Saar M. (Eds). The Pancreas (Two Volumes). Boston, Blackwell Scientific 1998 (pp 1644)[53]
Gress TM, Neoptolemos JP, Lemoine NR, Real FX (Eds). Exocrine pancreas cancer. The European Pancreatic Cancer-Research Cooperative (PC-RC). Felsenstein CCCP, Hannover. 2005 (pp 531)[55]
Neoptolemos JP and Bhutani MS. Fast Facts. Pancreas and Biliary Tree. Health Press Abingdon. 2006 (pp127)[56]
Neoptolemos JP and Ghaneh P (Eds). Cancer of the Pancreas. Best Practice & Research in Clinical Gastroenterology. London, Baillière Tindall[57]
Beger HG, Warshaw A, Büchler M, Kozarek R, Lerch M, Neoptolemos JP, Shiratori K, Whitcomb D. (Eds). The Pancreas, Second Edition. Blackwell Publishing, Massachusetts, US, 2008 (pp 1006)[58]
Neoptolemos JP, Urrutia R, Abbruzzese JL, Büchler MW (Eds). Pancreatic Cancer. Springer, New York, 2010. Two Volumes (pp1335)[59]
HG Beger HG, Nakao A, Neoptolemos JP, Peng SY, Sarr MG (Eds). Pancreatic Cancer, Cystic Neoplasms and Endocrine Tumors: Diagnosis and Management.Wiley Blackwell Publishers. 2018 (pp 436)[60]
Beger HG, Warshaw A, Hruban R, Büchler M, Lerch M, Neoptolemos JP, Tooru Shimosegawa, Whitcomb D. (Eds). The Pancreas, Third Edition. Blackwell Publishing, Massachusetts, US, 2018 (pp 1173)[61]
Neoptolemos JP, Urrutia R, Abbruzzese JL, Büchler MW (Eds). Pancreatic Cancer. Springer, New York. Second Edition. 2018. Three Volumes (pp 1642)[62]
Beger HG, Warshaw A, Hruban R, Büchler M, Lerch M, Neoptolemos JP, Tooru Shimosegawa, Whitcomb D. (Eds). The Pancreas, Third Edition. The Pancreas: An Integrated Textbook of Basic Science. Chinese Edition. John Wiley & Sons Limited Chichester, West Sussex, United Kingdom. PO19 8SQ. ISBN 978-1-119-18839-1. 2019[61]
^Neoptolemos, JP; Wood, P; Everson, NW; Bell, PR (September 1986). "The effect of surgical procedures on monocyte function in patients with carcinoma of the colon and rectum". Surgery, Gynecology & Obstetrics. 163 (3): 235–42. PMID3750179.
^Neoptolemos, J. P.; Dunn, J. A.; Stocken, D. D.; Almond, J.; Link, K.; Beger, H.; Bassi, C.; Falconi, M.; Pederzoli, P.; Dervenis, C.; Fernandez-Cruz, L.; Lacaine, F.; Pap, A.; Spooner, D.; Kerr, D. J.; Friess, H.; Büchler, M. W. (10 November 2001). "Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial". The Lancet. 358 (9293): 1576–1585. doi:10.1016/S0140-6736(01)06651-X. PMID11716884. S2CID23803289.
^Neoptolemos, John P.; Stocken, Deborah D.; Bassi, Claudio; Ghaneh, Paula; Cunningham, David; Goldstein, David; Padbury, Robert; Moore, Malcolm J.; Gallinger, Steven; Mariette, Christophe; Wente, Moritz N.; Izbicki, Jakob R.; Friess, Helmut; Lerch, Markus M.; Dervenis, Christos; Oláh, Attila; Butturini, Giovanni; Doi, Ryuichiro; Lind, Pehr A.; Smith, David; Valle, Juan W.; Palmer, Daniel H.; Buckels, John A.; Thompson, Joyce; McKay, Colin J.; Rawcliffe, Charlotte L.; Büchler, Markus W.; European Study Group for Pancreatic Cancer, for the (8 September 2010). "Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial". JAMA. 304 (10): 1073–1081. doi:10.1001/jama.2010.1275. PMID20823433.
^Neoptolemos, John P.; Moore, Malcolm J.; Cox, Trevor F.; Valle, Juan W.; Palmer, Daniel H.; McDonald, Alexander C.; Carter, Ross; Tebbutt, Niall C.; Dervenis, Christos; Smith, David; Glimelius, Bengt; Charnley, Richard M.; Lacaine, François; Scarfe, Andrew G.; Middleton, Mark R.; Anthoney, Alan; Ghaneh, Paula; Halloran, Christopher M.; Lerch, Markus M.; Oláh, Attila; Rawcliffe, Charlotte L.; Verbeke, Caroline S.; Campbell, Fiona; Büchler, Markus W.; European Study Group for Pancreatic Cancer, for the (11 July 2012). "Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma: The ESPAC-3 Periampullary Cancer Randomized Trial". JAMA. 308 (2): 147–156. doi:10.1001/jama.2012.7352. PMID22782416.